Urine collection and temporary storage device for radionuclide treatment patient

Abstract

The utility model relates to a radionuclide treatment patient urine collection and temporary storage device which comprises a funnel-type collector arranged on a portable pedestal pan, a urine temporary storage tank is arranged below the funnel-type collector, the urine temporary storage tank is composed of an inner barrel body and an outer protective sleeve, a funnel opening in the lower end of the funnel-type collector can be inserted into the inner barrel body, and the outer protective sleeve can be inserted into the funnel opening in the lower end of the funnel-type collector. Urine of a patient subjected to nuclide treatment is collected in the inner barrel body, protection of different radionuclides in the urine is achieved through the outer protection sleeve, the upper face and the lower face of the outer protection sleeve are provided with structures capable of being connected and positioned respectively, and multiple urine temporary storage tanks can be stacked up and down in multiple layers. The temporary storage tank is suitable for temporarily storing treatment nuclides emitting pure beta particles, such as 90Y, or treatment nuclides emitting beta particles accompanied by low-energy gamma rays, such as 177Lu and 161Tb. According to the utility model, a new treatment project can be carried out under the environment-friendly condition for a medical unit for developing radionuclide tumor treatment when the capacity of the decay pool is insufficient or no decay pool exists, so that the number of treated patients is increased.

Description

Technical Field

[0001] This utility model relates to a liquid collection and storage container, specifically to a device for collecting and temporarily storing urine from patients undergoing radionuclide therapy, used for the treatment of urine from patients undergoing radionuclide therapy for up to 10 hours after treatment. Background Technology

[0002] With an aging population, the incidence of malignant tumors in my country is increasing year by year, making it the second leading cause of death in the country. Early diagnosis and treatment can effectively control the incidence and mortality of malignant tumors. Among these treatments, radionuclide therapy is an effective means of controlling tumors, following surgery, radiotherapy, and chemotherapy. Currently, iodine-131 therapy is an effective method for treating thyroid cancer. Unlike conventional chemotherapy, patients undergoing radionuclide therapy should be hospitalized, and their excrement should not be directly discharged into the hospital's public sewage system. It should first undergo decay in a decay pool (GBZ20-2020) and only after reaching certain standards can it be treated as ordinary wastewater. In recent years, new radioactive isotopes have been applied clinically, such as Novartis's in 2018. 177 Lu-DOTA-TATE was approved by the FDA in 2022 for the treatment of gastrointestinal and pancreatic neuroendocrine tumors that overexpress somatostatin receptors. 177 Lu-PSMA-617 was approved by the FDA for the treatment of castration-resistant metastatic prostate cancer. In 2022, Grand Pharmaceutical Group's yttrium... 90 Y-resin microsphere injection has been approved for the treatment of patients with liver cancer and liver metastases from colorectal cancer.

[0003] With the application of new radioactive nuclides in hospitals, the following problems have arisen:

[0004] 1. The lack of a radionuclide decay pool prevents the implementation of corresponding treatments.

[0005] (1) Yttrium 90 After Y-resin microspheres are introduced into the human body via interventional methods, due to the presence of yttrium... 90 Y-resin microspheres undergo some dissolution in the body, resulting in a small amount of radioactive yttrium in the patient's urine. 90 "Y" will not be approved by the environmental protection department if there is no decay pool or if there is a decay pool but the toilet in the ward (area) is not connected to it.

[0006] (2) 177 Lu-DOTA-TATE and 177 After Lu-PSMA-617 is injected intravenously into the human body, more than 50% of its radioactivity is excreted in the urine within 8 hours. Patients receiving treatment in the nuclear medicine day ward require their radioactive waste to be disposed of in a decay pool, making it impossible for hospitals without decay pools to perform this procedure. 177 Lu radionuclide therapy program;

[0007] 2. Insufficient capacity of radionuclide decay pools

[0008] Most medical units that perform iodine-131 treatment have seen an increase in [number of cases / defects]. 177 Lu radionuclide therapy resulted in insufficient decay pool capacity. Due to... 177 Lu has a half-life of 6.73 days, requiring a relatively long period of natural decay. Article 8.6.2 of the "Basic Standards for Ionizing Radiation Protection and Radiation Source Safety" (GB 18871-2002) stipulates that wastewater from the decay pool, if monitoring results show that the iodine-131 activity concentration has decreased to no more than 10 Bq / L, can be directly discharged; or, after being stored in the decay pool for 180 days, it can also be discharged. Therefore, due to the restrictions of the Class B radiation safety permit, the addition of new nuclides will inevitably reduce the amount of iodine-131 used per unit, thus... 177 The number of patients receiving radionuclide therapy, such as Lu, is limited. Utility Model Content

[0009] The purpose of this invention is to address the problems existing in the prior art by providing a device for collecting and temporarily storing urine from patients undergoing radionuclide therapy, thereby solving the problems faced by hospitals in carrying out radionuclide therapy. 90 Y、 177 Lu and 161 The problem of insufficient decay pool capacity or lack of decay pools in the use of new therapeutic radionuclides such as Tb needs to be addressed to meet the needs of increasing the number of patients treated and adding new treatment wards while complying with environmental protection requirements.

[0010] To achieve the above objectives, the technical solution of this utility model is as follows:

[0011] A device for collecting and temporarily storing urine from patients undergoing radionuclide therapy includes a funnel-type collector mounted on a portable commode, and a urine storage tank located below the funnel-type collector. The urine storage tank consists of an inner container and an outer protective sleeve. The funnel opening at the lower end of the funnel-type collector can be inserted into the inner container to collect the urine of patients undergoing radionuclide therapy. The outer protective sleeve provides protection against different radionuclides in the urine.

[0012] Furthermore, in the aforementioned device for collecting and temporarily storing urine from patients undergoing radionuclide therapy, the outer protective cover includes a top cover and a container. The top surface of the top cover has an opening that matches the opening of the inner container. The inner container is placed inside the container, and the top cover and the container are fastened together.

[0013] Furthermore, in the urine collection and temporary storage device for patients undergoing radionuclide therapy as described above, the top surface of the outer protective cover and the bottom surface of the tank are respectively provided with structures that can be connected and positioned to each other, so as to realize the stacking of multiple urine storage tanks in multiple layers.

[0014] Specifically, the top surface of the outer protective sleeve is provided with a tenon structure, and the bottom surface of the tank is provided with a mortise structure, and the connection and positioning are achieved through the tenon and mortise combination.

[0015] Furthermore, in the urine collection and temporary storage device for patients undergoing radionuclide therapy as described above, a protective cover is provided at the opening on the top surface of the upper cover of the outer protective sleeve.

[0016] Furthermore, in the aforementioned device for collecting and temporarily storing urine from patients undergoing radionuclide therapy, the inner container is a plastic container; specifically, a commercially available drinking water bottle with a volume of 4L-20L can be used.

[0017] Furthermore, in the aforementioned device for collecting and temporarily storing urine from patients undergoing radionuclide therapy, the outer protective sleeve has a two-layer structure: an inner lead layer and an outer stainless steel layer, used to emit β particles accompanied by low-energy gamma rays from therapeutic radionuclides (such as...). 177 Lu and 161 Protection against nuclides such as Tb; lead layer thickness is 9-11mm, stainless steel layer thickness is 1-1.5mm.

[0018] Alternatively, the outer protective sleeve may be a single-layer structure made of plastic, used for emitting pure beta-particle therapeutic radionuclides (such as...). 90 Protection against nuclides such as Y.

[0019] The beneficial effects of this utility model are as follows:

[0020] The urine collection and temporary storage device for patients undergoing radionuclide therapy provided by this utility model can meet the needs of medical units to increase the number of patients being treated and to add new treatment wards, provided that it meets radiation safety operating conditions.

[0021] New medical project: Conducting [activities] in the absence of a radionuclide decay pool. 90 Y、 177 Lu、 161 Tb and other radionuclide therapy work;

[0022] New radionuclide therapy area: In wards (areas) without a connected decay pool, [the following measures will be implemented]. 90 Y-nuclide therapy work;

[0023] Increase the number of patients treated: When the decay pool capacity is insufficient, increase the number of patients receiving radionuclide therapy. Attached Figure Description

[0024] Figure 1 This is a schematic diagram of the structure of the urine collection and temporary storage device for patients undergoing radionuclide therapy according to this utility model;

[0025] Figure 2 This is a schematic diagram of the urine storage tank in the device of this utility model;

[0026] Figure 3 This is a schematic diagram of the top surface of the urine storage tank in the device of this utility model;

[0027] Figure 4 This is a schematic diagram of the bottom surface of the urine storage tank in the device of this utility model.

[0028] In the diagram: 1. Inner container (commercially available drinking water bottle); 2. Mortise and tenon joint; 3. Urine storage container; 4. Fastener.

[0029] 5. Mortise and tenon structure 6. Protective cover 7. Portable toilet 8. Funnel-type collector Detailed Implementation

[0030] The present invention will now be described in detail with reference to the accompanying drawings and embodiments.

[0031] like Figure 1 As shown, this utility model provides a urine collection and temporary storage device for patients undergoing radionuclide therapy, including a funnel-type collector 8 installed on a portable toilet 7, and a urine storage tank 3 installed below the funnel-type collector 8. The urine storage tank 3 consists of an inner barrel 1 and an outer protective sleeve. The funnel opening at the lower end of the funnel-type collector 8 can be inserted into the inner barrel 1 to collect the urine of patients who have received radionuclide therapy into the inner barrel 1. The outer protective sleeve protects the urine from different radionuclides.

[0032] This invention relates to the timely collection of urine from patients undergoing radionuclide therapy. It combines a portable commode with a protective urine storage container to temporarily store radioactive urine under protective conditions, treating it through decay. The portable commode has a funnel-shaped collector, allowing urine to flow directly into the storage container after urination. One container is used per patient, and the urine is processed only after sufficient storage time. The urine storage container is suitable for temporarily storing therapeutic nuclides that emit pure beta particles, such as: 90 Y, or emitting beta particles accompanied by low-energy gamma rays, such as therapeutic radionuclides. 177 Lu and 161 Tb, etc.

[0033] The urine storage container consists of an outer protective sleeve and an inner barrel. The inner barrel is a plastic barrel, which can be directly made of commercially available drinking water bottles for collecting urine and is also easy to seal after collection. Its capacity ranges from 4L to 20L.

[0034] The outer protective sleeve of the urine storage tank is made of two types of protective materials for different nuclides, one of which is specifically designed for... 90 Y-pure beta nuclide, protected with ordinary engineering plastics; another type targets... 177 Lu and 161For beta nuclides such as Tb accompanied by low-energy gamma rays, a double-layer structure of lead and stainless steel is used for protection. Specifically, the inner layer of the outer protective sleeve is a lead layer, and the outer layer is a stainless steel layer. The lead layer is 9-11 mm thick, and the stainless steel layer is 1-1.5 mm thick, to ensure that the surface dose rate of the outer protective sleeve of the temporary storage tank does not exceed 100 μSv / h.

[0035] like Figure 2 As shown, the outer protective sleeve of the urine storage tank 3 consists of two parts: a top cover and a tank body. The top cover and the tank body are connected by a fastener 4 to facilitate placement into a commercially available plastic bucket.

[0036] The outer protective sleeve of the urine storage tank has a special design. The top surface of the cover and the bottom surface of the tank are respectively equipped with structures that can be connected and positioned to each other, so as to allow multiple urine storage tanks to be stacked on top of each other, so as to store more urine storage tanks in a limited space.

[0037] As a specific implementation method, such as Figure 3 , Figure 4 As shown, the top surface of the outer protective cover has a tenon structure 2, and the bottom surface of the tank has a mortise structure 5. The connection and positioning are achieved through the tenon and mortise joint. The urine storage tank 3 can be stacked in multiple layers through the tenon and mortise combination, so as to store more storage tanks in a limited space. This is only one example of a structural form. Technicians can also design other connection and positioning structures, such as arc-shaped protrusions and corresponding arc-shaped grooves, etc., all of which can achieve the corresponding functions.

[0038] The method of using the urine collection and temporary storage device for patients undergoing radionuclide therapy according to this invention is as follows:

[0039] 1. Open the fastening of the outer protective cover of the urine storage container to separate the storage container into two parts: the top cover and the container body. Place the container into a commercially available plastic bucket (open the bucket lid) and then put the storage container back into place.

[0040] 2. After placing the urine storage container in a suitable location in the treatment ward, cover the storage container from top to bottom with the portable commode, and align the funnel-shaped collector on the portable commode with the opening of the plastic bucket to prevent urine from splashing out and causing contamination.

[0041] 3. Open the lid of the portable commode and allow the patient to urinate while seated so that the urine can be directly deposited into the plastic container inside the temporary storage tank.

[0042] 4. After the patient finishes using the portable commode within one day (8 hours), remove it from bottom to top, seal the plastic bucket with the lid, and put the protective cover on top.

[0043] 5. Move the urine storage container to the radioactive waste storage room and clearly mark the type of radionuclide and storage date in a prominent location; if there are multiple storage containers, they can be stacked using mortise and tenon joints to store more storage containers in a limited space.

[0044] 6. To 90 The urine storage tank for patients undergoing Y-nuclide therapy can directly pour radioactive urine into the toilet connected to the decay pool; or it can be placed in the radioactive waste storage room for 60 days (22 half-lives) and then treated as ordinary urine.

[0045] 7. To 177 Urine storage containers from Lu radionuclide therapy patients can be placed in a radioactive waste storage room for 70 days (10 half-lives) before being poured into a toilet connected to the decay pool for further decay to reduce pressure in the decay pool; alternatively, they can be placed in a radioactive waste storage room for 150 days (22 half-lives) before being treated as ordinary urine.

[0046] It will be apparent to those skilled in the art that the structure of this utility model is not limited to the details of the exemplary embodiments described above, and that the utility model can be implemented in other specific forms without departing from its spirit or essential characteristics. Therefore, the embodiments should be considered exemplary and non-limiting in all respects, and the scope of this utility model is defined by the appended claims rather than the foregoing description. Thus, it is intended that all variations falling within the meaning and scope of equivalents of the claims be included within this utility model. No reference numerals in the claims should be construed as limiting the scope of the claims.

[0047] Furthermore, it should be understood that although this specification describes embodiments, not every embodiment contains only one independent technical solution. This narrative style is merely for clarity. Those skilled in the art should consider the specification as a whole, and the technical solutions in each embodiment can also be appropriately combined to form other embodiments that can be understood by those skilled in the art.

Claims

1. A radionuclide therapy patient urine collection and temporary storage device, characterized in that, The application relates to a urine temporary storage tank, which comprises a funnel-shaped collector (8) arranged on a portable toilet (7), a urine temporary storage tank (3) arranged below the funnel-shaped collector (8), the urine temporary storage tank (3) being composed of an inner barrel (1) and an outer protective sleeve, and the lower end funnel of the funnel-shaped collector (8) can be inserted into the inner barrel to collect the urine of a patient after receiving a nucleotide treatment, and the outer protective sleeve realizes protection of different radioactive nucleotides in the urine.

2. The radionuclide therapy patient urine collection and temporary storage device of claim 1, wherein, The outer protective sleeve comprises an upper cover and a tank body, the upper surface of the upper cover is provided with an opening matched with the barrel opening of the inner barrel, the inner barrel is arranged in the tank body, and the upper cover and the tank body are combined through buckling positions (4).

3. The radionuclide therapy patient urine collection and temporary storage device of claim 2, wherein, The upper surface of the upper cover of the outer protective sleeve and the bottom surface of the tank body are respectively provided with structures capable of being connected and positioned with each other, so that multiple urine temporary storage tanks are stacked in multiple layers.

4. The radionuclide therapy patient urine collection and holding device of claim 3, wherein, The upper surface of the upper cover of the outer protective sleeve is provided with a tenon structure (2), the bottom surface of the tank body is provided with a mortise structure (5), and the tenon and the mortise are combined to realize connection and positioning.

5. The radionuclide therapy patient urine collection and holding device of claim 2, wherein, A protective cover (6) is arranged at the opening of the upper surface of the upper cover of the outer protective sleeve.

6. The radionuclide therapy patient urine collection and holding device of claim 1, wherein, The inner barrel (1) is a plastic barrel with a volume of 4L-20L.

7. The radionuclide therapy patient urine collection and temporary storage device of claim 6, wherein, The inner barrel (1) is a commercially available drinking water bottle.

8. The radionuclide therapy patient urine collection and temporary storage device of claim 1, wherein, The outer protective sleeve has a two-layer structure, the inner layer is a lead layer, and the outer layer is a stainless steel layer, which is used for protection of a treatment nucleotide emitting beta particles and low-energy gamma rays.

9. The radionuclide therapy patient urine collection and temporary storage device of claim 8, wherein, The thickness of the lead layer is 9-11mm, and the thickness of the stainless steel layer is 1-1.5mm.

10. The radionuclide therapy patient urine collection and temporary storage device of claim 1, wherein, The outer protective sleeve has a single-layer structure of a plastic material, which is used for protection of a pure beta particle treatment nucleotide.

Images